COVID-19 rapid guideline: managing COVID-19 (NG191)Product type:GuidanceProgramme:NICE guidelineLast updated: 30 November 2023Published: 23 March 2021
COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)Product type:GuidanceProgramme:NICE guidelineLast updated: 28 September 2023Published: 1 April 2020
Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 22 June 2023Published: 29 March 2023
Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 June 2023
COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)Product type:GuidanceProgramme:NICE guidelineLast updated: 11 November 2021Published: 18 December 2020
RespiraSense for continuously monitoring respiratory rate (MIB299)Product type:AdviceProgramme:Medtech innovation briefingPublished: 5 July 2022
SYNE-COV for predicting COVID-19 outcomes (MIB264)Product type:AdviceProgramme:Medtech innovation briefingPublished: 15 June 2021
URO17 for detecting bladder cancer (MIB250)Product type:AdviceProgramme:Medtech innovation briefingPublished: 4 February 2021
FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)Product type:AdviceProgramme:Medtech innovation briefingPublished: 26 August 2020
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)Product type:AdviceProgramme:Medtech innovation briefingPublished: 10 July 2020
COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 (ES24)Product type:AdviceProgramme:Evidence summaryPublished: 21 May 2020
COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis (ES26)Product type:AdviceProgramme:Evidence summaryPublished: 21 May 2020
COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES25)Product type:AdviceProgramme:Evidence summaryPublished: 21 May 2020
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)Product type:AdviceProgramme:Medtech innovation briefingPublished: 21 May 2020
COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES23)Product type:AdviceProgramme:Evidence summaryPublished: 14 April 2020
Lifelight First for monitoring vital signs (MIB213)Product type:AdviceProgramme:Medtech innovation briefingPublished: 8 April 2020
Managing COVID symptoms (including at the end of life) in a prison settingProduct type:Shared learningPublished: 6 April 2021
Project CARE: Supporting people with a positive diagnosis of COVID-19 and reaching out to those in vulnerable groupsProduct type:Shared learningPublished: 8 March 2021
Supporting and developing community end of life care during the COVID-19 pandemic: an example of collaborative workingProduct type:Shared learningPublished: 1 December 2020
Developing and implementing guidance for staff delegating clinical tasks to informal carers and relatives during the COVID-19 pandemicProduct type:Shared learningPublished: 2 September 2020
Maintaining a cancer service in the midst of the COVID-19 pandemic: A single centre experienceProduct type:Shared learningPublished: 3 August 2020